Methods and compositions for the treatment of inflammation
The present invention comprises methods and compositions for the treatment and prevention of inflammatory conditions. The compositions comprise polymers and copolymers that are effective in modulating the activity of enzymes associated with inflammatory conditions. The methods comprise administration of effective amounts of such compositions to treat or prevent inflammatory conditions to sites of inflammation or potential inflammation.
1 . A method for treating inflammatory conditions, comprising, administering a composition comprising at least one acrylic-acid based polymer in an amount that is effective in modulating the activity of at least one enzyme associated with inflammatory conditions.
2 . The method of claim 1 , wherein the at least one acrylic acid based polymer is a linear acrylic acid-based polymer, a cross-linked acrylic acid-based polymer, an high molecular weight cross-linked acrylic acid-based polymer, polymers of acrylic acid cross-linked with allyl sucrose, a polymer of acrylic acid cross-linked with allylpentaerythritol, a polymers of acrylic acid modified by long chain (C10-C30) acrylates, a polymers of acrylic acid modified by long chain (C10-C30) acrylates that are cross-linked with allylpentaerythritol, a copolymer of acrylic acid modified by long chain (C10-C30) alkyl acrylates, a copolymers of acrylic acid modified by long chain (C10-C30) alkyl acrylates cross-linked with allylpentaerythritol, a polymer of acrylic acid cross-linked with divinyl glycol, an homopolymer of acrylic acid cross-linked with an allyl ether of penaethritol, an allyl ether of sucrose or an allyl ether of propylene, a polyvinyl carboxy polymer, a carbomer, a copolymer of C-10 to C-30 alkyl acrylates and one or more monomers of acrylic acid, methacrylic acid or one of their simple esters cross-linked with an allyl ether of sucrose or an allyl ether of pentaerythritol, a graft copolymer with acrylic polymer backbone and dimethylpolysiloxane side chains, an hydrophilic/hydrophobic block copolymer such as an ammonium acylate or an acrylonitrogen copolymer, an acrylic and acrylonitrogen copolymer, an acrylic acid polyquaternium copolymer, a polyglycol, an hydrophobically modified ethylene oxide urethane, polymer or copolymer.
3 . The method of claim 1 , wherein in the compositions, the amount of the at least one acrylic-acid polymer is from about 0.001% wt to 95% wt.
4 . The method of claim 1 , wherein the at least one enzyme is peptide hydrolases, serine proteases, matrix metalloproteinases, collagenases, kinases, elastases or peroxydases.
5 . The method of claim 1 , wherein the inflammatory condition comprises skin reactions, allergic reactions, asthma, lung diseases or responses, kidney diseases, acute inflammatory diseases, vascular inflammatory disease, chronic inflammation, atherosclerosis, immune related diseases, angiopathy, myocarditis, nephritis, Crohn's disease, wound healing, arthritis, or type I or II diabetes and the associated vascular pathologies.
6 . The method of claim 1 , wherein the composition further comprises one or more formulation components including pharmaceutical excipient, preservative, emulsifier, emollient, rheology modifying agent, skin-feel additive, moisturizing agent, humectant, film former, pH adjuster/chelating agent, fragrance, effect pigment, color additive, water or combinations thereof.
7 . The method of claim 1 , wherein administering comprises applying the composition to the skin or other body surface.
8 . The method of claim 1 , wherein administering comprises applying the composition one or more time daily until the inflammatory condition subsides or ceases.
9 . The method of claim 1 , wherein the composition comprises an oil and water emulsion comprising 0.01% wt acrylic acid polymer, wherein the acrylic acid polymer is an acrylate/C10-30 alkyl acrylate crosspolymer.
10 . A method of preventing inflammatory conditions, comprising, administering an amount of a one composition comprising at least one acrylic-acid based polymer that is effective in modulating the activity of at least one enzyme associated with inflammatory conditions.
11 . The method of claim 10 , wherein the at least one acrylic acid based polymer is a linear acrylic acid-based polymer, a cross-linked acrylic acid-based polymer, an high molecular weight cross-linked acrylic acid-based polymer, polymers of acrylic acid cross-linked with allyl sucrose, a polymer of acrylic acid cross-linked with allylpentaerythritol, a polymers of acrylic acid modified by long chain (C10-C30) acrylates, a polymers of acrylic acid modified by long chain (C10-C30) acrylates that are cross-linked with allylpentaerythritol, a copolymer of acrylic acid modified by long chain (C10-C30) alkyl acrylates, a copolymers of acrylic acid modified by long chain (C10-C30) alkyl acrylates cross-linked with allylpentaerythritol, a polymer of acrylic acid cross-linked with divinyl glycol, an homopolymer of acrylic acid cross-linked with an allyl ether of penaethritol, an allyl ether of sucrose or an allyl ether of propylene, a polyvinyl carboxy polymer, a carbomer, a copolymer of C-10 to C-30 alkyl acrylates and one or more monomers of acrylic acid, methacrylic acid or one of their simple esters cross-linked with an allyl ether of sucrose or an allyl ether of pentaerythritol, a graft copolymer with acrylic polymer backbone and dimethylpolysiloxane side chains, an hydrophilic/hydrophobic block copolymer such as an ammonium acylate or an acrylonitrogen copolymer, an acrylic and acrylonitrogen copolymer, an acrylic acid polyquaternium copolymer, a polyglycol, an hydrophobically modified ethylene oxide urethane, polymer or copolymer.
12 . The method of claim 10 , wherein in the compositions, the amount of the at least one acrylic-acid polymer is from about 0.001% wt to 95% wt.
13 . The method of claim 10 , wherein the at least one enzyme is peptide hydrolases, serine proteases, matrix metalloproteinases, collagenases, kinases, elastases or peroxydases.
14 . The method of claim 10 , wherein the inflammatory condition comprises skin reactions, allergic reactions, asthma, lung diseases or responses, kidney diseases, acute inflammatory diseases, vascular inflammatory disease, chronic inflammation, atherosclerosis, immune related diseases, angiopathy, myocarditis, nephritis, Crohn's disease, wound healing, arthritis, or type I or II diabetes and the associated vascular pathologies.
15 . The method of claim 10 , wherein the composition further comprises one or more formulation components including pharmaceutical excipient, preservative, emulsifier, emollient, rheology modifying agent, skin-feel additive, moisturizing agent, humectant, film former, pH adjuster/chelating agent, fragrance, effect pigment, color additive, water or combinations thereof.
16 . The method of claim 10 , wherein administering comprises applying the composition to the skin or other body surface.
17 . The method of claim 10 , wherein administering comprises applying the composition one or more time daily until the inflammatory condition subsides or ceases.
18 . The method of claim 10 , wherein the composition comprises an oil and water emulsion comprising 0.01% wt acrylic acid polymer, wherein the acrylic acid polymer is an acrylate/C10-30 alkyl acrylate crosspolymer.
19 . A composition comprising, at least one acrylic acid based polymer, in an amount effective to modulate the activity of at least one enzyme associated with an inflammatory condition, wherein the amount of the acrylic acid based polymer is less than 95% wt of the composition.
20 . The composition of claim 19 , wherein the amount of the acrylic acid based polymer is less than 0.05% wt of the composition.